| Literature DB >> 26640469 |
Niha Dhar1, Sumeer Razdan1, Satiander Rana1, Wajid W Bhat1, Ram Vishwakarma2, Surrinder K Lattoo1.
Abstract
Withania somnifera, a multipurpose medicinal plant is a rich reservoir of pharmaceutically active triterpenoids that are steroidal lactones known as withanolides. Though the plant has been well-characterized in terms of phytochemical profiles as well as pharmaceutical activities, limited attempts have been made to decipher the biosynthetic route and identification of key regulatory genes involved in withanolide biosynthesis. This scenario limits biotechnological interventions for enhanced production of bioactive compounds. Nevertheless, recent emergent trends vis-à-vis, the exploration of genomic, transcriptomic, proteomic, metabolomics, and in vitro studies have opened new vistas regarding pathway engineering of withanolide production. During recent years, various strategic pathway genes have been characterized with significant amount of regulatory studies which allude toward development of molecular circuitries for production of key intermediates or end products in heterologous hosts. Another pivotal aspect covering redirection of metabolic flux for channelizing the precursor pool toward enhanced withanolide production has also been attained by deciphering decisive branch point(s) as robust targets for pathway modulation. With these perspectives, the current review provides a detailed overview of various studies undertaken by the authors and collated literature related to molecular and in vitro approaches employed in W. somnifera for understanding various molecular network interactions in entirety.Entities:
Keywords: Withania somnifera; elicitor; medicinal plant; molecular cloning; pathway engineering; secondary metabolites; tissue culture; withanolides
Year: 2015 PMID: 26640469 PMCID: PMC4661287 DOI: 10.3389/fpls.2015.01031
Source DB: PubMed Journal: Front Plant Sci ISSN: 1664-462X Impact factor: 5.753
Figure 1The basic structure of withanolide.
Figure 2An overview of putative withanolide biosynthesic pathway. DXP, 1-deoxy-D-xylulose 5-phosphate; HMBDP, 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate; IPP, Isopentylpyrophosphate; DMPP, Dimethylalyl diphosphate; IPP isomerase, Isopentylpyrophosphate isomerase; FPPS, farnesyldiphosphate synthase; SQS, Squalene synthase; SQE/CPR, Squalene epoxidase/cytochrome P450 reductase; CAS, Cycloartenol synthase; SMT-1, Sterol methyl transferase/cytochrome P450 reductase; ODM/CPR, Obtusifoliol-14-demethylase/cytochrome P450 reductase. First three highlighted (yellow) steps indicating involvement of P450 monooxygenases and CPR. Single dark arrows represent one step, two or more dark arrows represent multiple steps and dashed arrow represents unknown steps.
Putative pathway genes from .
| 3-Hydroxy-3-methylglutaryl coenzyme A reductase | Salicylic acid, methyl-jasmonate, and mechanical injury | |||
| Salt, heat, and cold | Increase in | |||
| 1-Deoxy-D-xylulose-5-phosphate synthase | Salicylic acid, methyl jasmonate, mechanical injury | Maximum expression in flower and young leaves | ||
| 1-Deoxy-D-xylulose-5-phosphate reductase | Salicylic acid, methyl jasmonate, mechanical injury | Differentially expressed in different tissues | ||
| Methyl jasmonate salicylic acid, gibberellic acid | Methyl jasmonate salicylic acid increased and gibberellic acid decreased | |||
| WS-3 accumulation increased upon methyl jasmonate elicitation; gibberellic acid treatment decreased WS-3 and WS-1 accumulation | ||||
| Methyl jasmonate, salicylic acid, gibberellic acid | Methyl jasmonate, salicylic acid as positive regulators and gibberellic acid acted as a negative regulator for | |||
| Methyl jasmonate elicitation increased WS-3 accumulation; gibberellic acid decreased WS-3 and WS-1 accumulation | ||||
| Methyl jasmonate, salicylic acid | The expression remained unchanged in | |||
| Methyl jasmonate, salicylic acid | The treatments with methyl jasmonate, salicylic acid resulted in induction of | |||
| Methyl jasmonate, salicylic acid | Withanolides were regulated by methyl-jasmonate, salicylic acid and 2,4-D, treatments | |||
| Methyl jasmonate, salicylic acid | Biosynthesis of withanolide was up-regulated by methyl-jasmonate, salicylic acid and 2,4-D | |||
| Oxidosqualene cyclases (OSCs) | Methyl jasmonate, gibberellic acid and yeast extract | Upon methyl jasmonate treatment transcript levels of | ||
| Methyl jasmonate, gibberellic acid and 2,4-D | The treatments with methyl jasmonate, 2,4-D and salicylic acid resulted increased expression of | |||
| Transcripts | ||||
| Methyl jasmonate, salicylic acid, mechanical injury | Maximum expression was found in flower and young leaf and NMITLI-101 chemotype. Significant elevation in response to salicylic acid, methyl jasmonate and mechanical injury |
.
| (a) Supplementation with 2.0 mg L−1 2,4-D and 2.0 mg L−1 2,4-D + 0.5 mg L−1 kinetin | (a) 1.27 mg g−1 DWB of WS-1 | |
| (a) Supplementation with 1.00 ppm benzylaminopurine and 0.50 ppm kinetin | (a) 14.3 mg per 100 g FWB and 238 mg per 100 g DWB of WS-1 | |
| (a) MS-based liquid medium supplemented with 40 g/L sucrose for hairy roots | (a) 2.7-fold higher WS-1 (b) 64.65 mg g−1 DWB of WS-1 (48-fold), 33.74 mg g−1 DWB of withanolide B (29-fold), 17.47 mg g−1 DWB WS-3 (20-fold), 42.88 mg g−1 DWB WS-2 (37-fold), 5.34 mg g−1 DWB 12-deoxy withastramonolide (nine-fold), 7.23 mg g−1 DWB withanoside V (seven-fold), and 9.45 mg g−1 DWB withanoside IV | |
| Somaclonal variants | Somaclonal variant regenerated with 0.516% (DWB) of 12-deoxywithastramonolide | |